Clinical trial results and treatment resistance with lamivudine in hepatitis B
- PMID: 15192799
- DOI: 10.1055/s-2004-828676
Clinical trial results and treatment resistance with lamivudine in hepatitis B
Abstract
Lamivudine is an effective first-line therapy for chronic hepatitis B virus (HBV) infection, accomplishing the goals of viral suppression, normalization of alanine aminotransferase (ALT) levels, histological improvement, and seroconversion. In the lamivudine clinical trials, up to 32% of patients positive for hepatitis B e antigen (HBeAg) lost HBeAg after 1 year of treatment, and approximately 18% achieved HBeAg seroconversion. ALT levels greater than five times the upper limit of normal increased the likelihood of HBeAg loss. The rates of seroconversion and resistance both increase with the length of treatment. In HBeAg-negative patients, two thirds showed response after 6 to 12 months of therapy, but this response diminished over time despite continued treatment, largely due to the emergence of resistance. Resistance is present in nearly 70% of patients at 5 years. Resistance reverses prior biochemical, virological, and histological gains and can lead to progressive liver failure. Careful patient selection is important, therefore, to maximize the potential for a treatment response under limited therapy.
Similar articles
-
Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.Hepatology. 2001 Jun;33(6):1527-32. doi: 10.1053/jhep.2001.25084. Hepatology. 2001. PMID: 11391543 Clinical Trial.
-
Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.Am J Gastroenterol. 2005 Nov;100(11):2463-71. doi: 10.1111/j.1572-0241.2005.00247.x. Am J Gastroenterol. 2005. PMID: 16279901 Clinical Trial.
-
An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.Chin Med J (Engl). 2002 Dec;115(12):1814-8. Chin Med J (Engl). 2002. PMID: 12622930 Clinical Trial.
-
Efficacy of lamivudine in HBeAg-negative chronic hepatitis B.J Med Virol. 2002 Apr;66(4):435-51. J Med Virol. 2002. PMID: 11857520 Review.
-
Treatment of chronic hepatitis B virus infection - Dutch national guidelines.Neth J Med. 2008 Jul-Aug;66(7):292-306. Neth J Med. 2008. PMID: 18663260 Review.
Cited by
-
Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis.World J Gastroenterol. 2013 Oct 28;19(40):6849-56. doi: 10.3748/wjg.v19.i40.6849. World J Gastroenterol. 2013. PMID: 24187460 Free PMC article.
-
Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment.World J Gastroenterol. 2006 Sep 7;12(33):5301-5. doi: 10.3748/wjg.v12.i33.5301. World J Gastroenterol. 2006. PMID: 16981258 Free PMC article.
-
Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D.World J Gastroenterol. 2011 Dec 7;17(45):4987-92. doi: 10.3748/wjg.v17.i45.4987. World J Gastroenterol. 2011. PMID: 22174548 Free PMC article.
-
Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab.Infection. 2019 Feb;47(1):59-65. doi: 10.1007/s15010-018-1214-5. Epub 2018 Sep 19. Infection. 2019. PMID: 30232604
-
Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen.J Virol. 2009 Feb;83(4):1718-26. doi: 10.1128/JVI.02011-08. Epub 2008 Dec 10. J Virol. 2009. PMID: 19073746 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
